Sarepta Therapeutics has experimental Ebola drug available for use claims CEO Chris Garabedian. The drug, dubbed AVI-7537 works against the VP24 protein in the Ebola virus organism.
The drug has been tested for safety in a Phase I clinical trial. The manufacturer claims that if a request was made and the appropriate clearances were granted by government regulators, they could have AVI-7537 on the ground in West Africa within one week in sufficient quantity to start treating significant numbers of patients.
Ebola patients often experience hemorrhaging from the eyes, skin, mouth, and rectum. Patients most commonly die of multisystem organ failure of the kidneys, lungs, liver, and heart.